According to TG Therapeutics's latest financial reports the company has a price-to-book ratio of 18.5.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 16.1 | -45.1% |
2022-12-31 | 29.3 | 156.26% |
2021-12-31 | 11.5 | -17.03% |
2020-12-31 | 13.8 | -56.1% |
2019-12-31 | 31.4 | 119.78% |
2018-12-31 | 14.3 | 65.43% |
2017-12-31 | 8.65 | 21.88% |
2016-12-31 | 7.10 | 11.76% |
2015-12-31 | 6.35 | -28.55% |
2014-12-31 | 8.89 | 166.09% |
2013-12-31 | 3.34 | -44.75% |
2012-12-31 | 6.04 | 38872.27% |
2011-12-31 | 0.0155 | -103.82% |
2010-12-31 | -0.4059 | -48.01% |
2009-12-31 | -0.7807 | 504.64% |
2008-12-31 | -0.1291 | -98.19% |
2007-12-31 | -7.13 | -123.18% |
2006-12-31 | 30.8 | 290.77% |
2005-12-31 | 7.87 | 27.69% |
2004-12-31 | 6.17 | 14.13% |
2003-12-31 | 5.40 | 238.12% |
2002-12-31 | 1.60 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Alkermes ALKS | 3.26 | -82.39% | ๐ฎ๐ช Ireland |
Dr. Reddy's RDY | 3.74 | -79.79% | ๐ฎ๐ณ India |